Literature DB >> 31917160

Gut microbiota: A new piece in understanding hepatocarcinogenesis.

An Zhou1, Li Tang1, Shuo Zeng1, Yuanyuan Lei1, Shiming Yang2, Bo Tang3.   

Abstract

The gut microbiota forms a symbiotic relationship with the host and benefits the body in many critical aspects of life. However, immune system defects, alterations in the gut microbiota and environmental changes can destroy this symbiotic relationship and may lead to diseases, including cancer. Due to the anatomic and functional connection of the gut and liver, increasing studies show the important role of the gut microbiota in the carcinogenesis of hepatocellular carcinoma (HCC). In this manuscript, we review the available evidence and analyze some potential mechanisms of the gut microbiota, including bacterial dysbiosis, lipopolysaccharide (LPS), and genotoxins, in the progression and promotion of HCC. Furthermore, we discuss the possible therapeutic applications of probiotics, chemotherapy modulation, immunotherapy, targeted drugs and fecal microbiota transplantation (FMT) in targeting the gut microbiota.
Copyright © 2020 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Carcinogenesis; Dysbiosis; Hepatocellular carcinoma; Microbiota; Probiotics

Mesh:

Year:  2020        PMID: 31917160     DOI: 10.1016/j.canlet.2020.01.002

Source DB:  PubMed          Journal:  Cancer Lett        ISSN: 0304-3835            Impact factor:   8.679


  9 in total

1.  Hepatocellular carcinoma immunotherapy: The impact of epigenetic drugs and the gut microbiome.

Authors:  Farzam Vaziri; Steven Colquhoun; Yu-Jui Yvonne Wan
Journal:  Liver Res       Date:  2020-10-17

Review 2.  Hepatocellular Carcinoma: How the Gut Microbiota Contributes to Pathogenesis, Diagnosis, and Therapy.

Authors:  Wenyu Luo; Shiqi Guo; Yang Zhou; Jingwen Zhao; Mengyao Wang; Lixuan Sang; Bing Chang; Bingyuan Wang
Journal:  Front Microbiol       Date:  2022-04-27       Impact factor: 6.064

3.  Defining the temporal evolution of gut dysbiosis and inflammatory responses leading to hepatocellular carcinoma in Mdr2 -/- mouse model.

Authors:  J Behary; A E Raposo; N M L Amorim; H Zheng; L Gong; E McGovern; J Chen; K Liu; J Beretov; C Theocharous; M T Jackson; J Seet-Lee; G W McCaughan; E M El-Omar; A Zekry
Journal:  BMC Microbiol       Date:  2021-04-15       Impact factor: 3.605

Review 4.  Roles of Microbiota in Cancer: From Tumor Development to Treatment.

Authors:  Zohreh Bagheri; Leila Moeinzadeh; Mahboobeh Razmkhah
Journal:  J Oncol       Date:  2022-03-23       Impact factor: 4.375

Review 5.  Gut Microbiota and Immunotherapy.

Authors:  Xiaoqing Xu; Jieer Ying
Journal:  Front Microbiol       Date:  2022-07-01       Impact factor: 6.064

Review 6.  Gut Microbiota as Potential Biomarker and/or Therapeutic Target to Improve the Management of Cancer: Focus on Colibactin-Producing Escherichia coli in Colorectal Cancer.

Authors:  Julie Veziant; Romain Villéger; Nicolas Barnich; Mathilde Bonnet
Journal:  Cancers (Basel)       Date:  2021-05-05       Impact factor: 6.639

7.  Densely Functionalized 2-Methylideneazetidines: Evaluation as Antibacterials.

Authors:  Giovanni Petrillo; Cinzia Tavani; Lara Bianchi; Alice Benzi; Maria Maddalena Cavalluzzi; Lara Salvagno; Laura Quintieri; Annalisa De Palma; Leonardo Caputo; Antonio Rosato; Giovanni Lentini
Journal:  Molecules       Date:  2021-06-25       Impact factor: 4.411

8.  Firmicutes in Gut Microbiota Correlate with Blood Testosterone Levels in Elderly Men.

Authors:  Makoto Matsushita; Kazutoshi Fujita; Daisuke Motooka; Koji Hatano; Junya Hata; Mitsuhisa Nishimoto; Eri Banno; Kentaro Takezawa; Shinichiro Fukuhara; Hiroshi Kiuchi; Yue Pan; Toshifumi Takao; Akira Tsujimura; Shinichi Yachida; Shota Nakamura; Wataru Obara; Hirotsugu Uemura; Norio Nonomura
Journal:  World J Mens Health       Date:  2022-02-24       Impact factor: 6.494

9.  Characterization of gut microbiota in patients with primary hepatocellular carcinoma received immune checkpoint inhibitors: A Chinese population-based study.

Authors:  Lili Li; Jiajian Ye
Journal:  Medicine (Baltimore)       Date:  2020-09-11       Impact factor: 1.817

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.